newswire, breaking biotechnology and pharma news

Monday, February 9, 2015

GenSpera (OTCQB:GNSZ) Announces Partnership With Global Supplier

Biotech News Alert: GenSpera (OTCQB:GNSZ) Announces Partnership With Global Supplier

Company to Partner with Phyton Biotech for Manufacture of the Key Ingredient in Mipsagargin

SAN ANTONIO - February 9, 2015 ( Biotech Newswire) GenSpera, Inc. (OTCQB:GNSZ) today announced a strategic partnership with Phyton Biotech for the manufacture of thapsigargin, which is derived from the thapsia plant and is the key ingredient in the company's investigational agent mipsagargin. Phyton Biotech will offer its Plant Cell Fermentation (PCF®) development expertise to convert the thapsia plant into a preserved, fermentable cell line with a goal of creating a sustainable source of high quality thapsigargin.

"This partnership will revolutionize the way we obtain thapsigargin to develop our drugs, enabling us to boost supply and reduce the impurities that can arise when it is extracted from naturally grown plants," said Craig Dionne, Ph.D., chief executive officer at GenSpera. "By working with Phyton Biotech, we are leveraging state-of-the-art biotech that has the potential to improve the efficiency of our production process. It is through these kinds of partnerships that we can not only develop new drug candidates, but do so in a way that creates increased product value."

The announcement comes as GenSpera enters a stage of continued development of mipsagargin in hepatocellular carcinoma (HCC) and ongoing trials in glioblastoma (brain cancer) and prostate cancer. This week, GenSpera will present its long-term business growth plans at the BIO CEO & Investor conference being held in New York City. Last month, GenSpera presented positive Phase II study results for mipsagargin in treating HCC at the 2015 Gastrointestinal Cancers Symposium in San Francisco, Calif., demonstrating a proof of concept for its intellectual property.

"Working with an innovative partner like GenSpera, who is committed to developing new treatment options and doing so in a way that maximizes efficiency and quality, is exciting," said Mark Mitchell, president at Phyton Biotech. "Phyton has a proven track record for commercial supply of active pharmaceutical ingredients in the field of oncology using its PCF process. We share GenSpera's vision of harnessing the power of the thapsia plant and expanding their capacity with the best biotech."

About Phyton
Phyton Biotech is the pioneer in Plant Cell Fermentation (PCF®) for the development and manufacture of plant-based active ingredients and other complex molecules. Phyton Biotech's development services business is focused on harnessing plant-derived natural actives and products for use in the pharmaceutical field (APIs) as well as in food ingredients, cosmetic, and agricultural industries. Utilizing a proprietary PCF® platform technology, Phyton offers a time, risk, and cost balanced path to commercially viable production processes, resulting in the addition of sustainability, reliability, quality and scalability to a supply chain of an API. Phyton's unique capabilities address the entire development chain, including selection and sourcing of plant material, cell line development, process development, down-stream development, chemical processing, scale-up, and commercial production. Phyton is also the world's largest commercial provider of high quality Paclitaxel and Docetaxel API via PCF® to a global customer base of sterile injectable manufacturers. The company has GMP facilities in Ahrensberg, Germany and Vancouver, Canada.

For additional information on Phyton Biotech, visit

About GenSpera
GenSpera Inc. is a San Antonio-based biotech company that unlocks conventional thinking to conceive, design, and develop cancer therapies. GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides for the targeted release of drug candidates within tumors. GenSpera's lead drug candidate, mipsagargin, was granted Orphan Drug designation by the US Food and Drug Administration (FDA) in 2013 for evaluation in patients with hepatocellular carcinoma (liver cancer).

For additional information on GenSpera, visit and connect on Twitter @GenSperaNews, LinkedIn, Facebook, YouTube and Google+.

Cautionary Statement Regarding Forward Looking Information
This communication may contain forward-looking statements. Investors are cautioned that statements in this document regarding potential applications of GenSpera's technologies or the future prospects of the company constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights and the acceptance of GenSpera's proposed therapies by the health community. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.

Disclaimer/Disclosure: The newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: GNSZ is a previous showcase company which expired on December 18, 2014. Investorideas is long 144 shares

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: Global investors must adhere to regulations of each country.

Become an Member and access our 14 online stock directories 24/7 –biotech, mining stocks, oil and gas stocks and more... 

1 comment:

  1. international updates of stock exchange, The Hang Seng index climbed 3.8 percent to its highest level since May 2008 in the previous session, boosted by strong buying from Chinese investors.

    stock tips